The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…

NBIX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.30%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $65,104,745.00

Neurocrine Biosciences Insider Trading History Chart

Neurocrine Biosciences Share Price & Price History

^$138.89

▲ +2.9 (2.13%)

As of 04/29/2024 06:27 PM ET

Days: 30 | 90 | 365

The “Next Bitcoin”? 10 CENT Crypto Set to Explode

From True Market Insiders | Ad

The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…

Click For My #1 FREE Crypto for 2024

Neurocrine Biosciences Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/15/2024	Eric Benevich	Insider	Sell	19,818	$133.36	$2,642,928.48	40,778
3/21/2024	Ingrid Delaet	Insider	Sell	5,000	$145.06	$725,300.00	7,507
3/14/2024	Eric Benevich	Insider	Sell	75,000	$139.38	$10,453,500.00	40,778
3/14/2024	George J. Morrow	Director	Sell	40,000	$139.42	$5,576,800.00
3/11/2024	Ingrid Delaet	Insider	Sell	200	$140.00	$28,000.00	7,507
3/11/2024	Richard F. Pops	Director	Sell	100	$140.00	$14,000.00	29,512
3/8/2024	Ingrid Delaet	Insider	Sell	1,800	$140.03	$252,054.00	7,507
3/8/2024	Richard F. Pops	Director	Sell	1,700	$140.05	$238,085.00	29,512
2/29/2024	Ingrid Delaet	Insider	Sell	273	$135.51	$36,994.23	7,507
2/27/2024	Leslie V. Norwalk	Director	Sell	8,000	$135.67	$1,085,360.00
2/20/2024	Richard F. Pops	Director	Sell	15,000	$132.47	$1,987,050.00	29,512
2/13/2024	Eiry Roberts	Insider	Sell	1,114	$132.96	$148,117.44	23,716
2/13/2024	Kevin Charles Gorman	CEO	Sell	2,832	$133.02	$376,712.64	514,596
2/13/2024	Matt Abernethy	CFO	Sell	1,352	$132.85	$179,613.20	31,528
2/8/2024	David W. Boyer	Insider	Sell	1,328	$135.41	$179,824.48	4,895
2/8/2024	Kevin Charles Gorman	CEO	Sell	2,274	$134.15	$305,057.10	506,962
2/8/2024	Matt Abernethy	CFO	Sell	980	$134.21	$131,525.80	30,314
2/6/2024	David W. Boyer	Insider	Sell	456	$141.96	$64,733.76	4,894
2/6/2024	Kevin Charles Gorman	CEO	Sell	3,040	$142.18	$432,227.20	504,919
2/6/2024	Matt Abernethy	CFO	Sell	1,280	$142.19	$182,003.20	29,434
1/31/2024	Eiry Roberts	Insider	Sell	1,457	$140.79	$205,131.03	20,832
1/31/2024	Kevin Charles Gorman	CEO	Sell	2,707	$140.69	$380,847.83	502,188
1/31/2024	Matt Abernethy	CFO	Sell	1,283	$140.72	$180,543.76	28,284
1/22/2024	Darin Lippoldt	Insider	Sell	10,000	$139.86	$1,398,600.00	35,882
1/8/2024	Kevin Charles Gorman	CEO	Sell	105,835	$132.44	$14,016,787.40	499,754
1/2/2024	Kyle Gano	Insider	Sell	75,000	$131.47	$9,860,250.00	130,250
1/2/2024	William H. Rastetter	Director	Sell	11,044	$131.47	$1,451,954.68	51,741
12/22/2023	Eiry Roberts	Insider	Sell	10,000	$126.74	$1,267,400.00	19,521
12/12/2023	Eiry Roberts	Insider	Sell	13,925	$120.30	$1,675,177.50	29,521
12/8/2023	Eiry Roberts	Insider	Sell	300	$120.10	$36,030.00	29,521
12/6/2023	Darin Lippoldt	Insider	Sell	20,830	$119.86	$2,496,683.80	35,882
12/1/2023	Gary A. Lyons	Director	Sell	5,000	$116.77	$583,850.00	203,697
11/29/2023	Jude Onyia	Insider	Sell	2,331	$113.57	$264,731.67	11,732
11/27/2023	Darin Lippoldt	Insider	Sell	10,919	$112.27	$1,225,876.13	35,882
10/2/2023	David W. Boyer	Insider	Sell	1,437	$112.68	$161,921.16	4,894
9/12/2023	Gary A. Lyons	Director	Sell	5,000	$115.02	$575,100.00	203,697
9/1/2023	Gary A. Lyons	Director	Sell	5,000	$110.06	$550,300.00	203,697
9/1/2023	Julie Cooke	Insider	Sell	824	$110.93	$91,406.32	17,263
8/30/2023	David W. Boyer	Insider	Sell	2,733	$107.60	$294,070.80	3,460
8/28/2023	Ingrid Delaet	Insider	Sell	1,431	$107.52	$153,861.12	5,931
8/21/2023	Jude Onyia	Insider	Sell	3,198	$107.37	$343,369.26	9,638
8/21/2023	Kevin Charles Gorman	CEO	Sell	9,328	$107.40	$1,001,827.20	499,754
8/21/2023	Matt Abernethy	CFO	Sell	2,132	$107.39	$228,955.48	27,131
5/1/2023	Julie Cooke	Insider	Sell	11,397	$103.89	$1,184,034.33	16,169
5/1/2023	William H. Rastetter	Director	Sell	4,300	$101.43	$436,149.00	42,785
4/24/2023	Eiry Roberts	Insider	Sell	14,400	$103.48	$1,490,112.00	26,644
4/21/2023	William H. Rastetter	Director	Sell	6,034	$105.04	$633,811.36	39,460
4/19/2023	William H. Rastetter	Director	Sell	903	$105.00	$94,815.00	34,729
2/23/2023	Neurocrine Biosciences Inc	Major Shareholder	Buy	4,395,588	$8.88	$39,032,821.44	8,575,316
2/8/2023	Eric Benevich	Insider	Sell	980	$104.12	$102,037.60	34,381
2/8/2023	Kevin Charles Gorman	CEO	Sell	2,274	$104.30	$237,178.20	491,365
2/7/2023	Matt Abernethy	CFO	Sell	26,328	$102.40	$2,695,987.20	24,333
2/6/2023	Eric Benevich	Insider	Sell	1,280	$105.63	$135,206.40	17,879
2/6/2023	Kevin Charles Gorman	CEO	Sell	3,040	$105.68	$321,267.20	468,008
1/31/2023	Eiry Roberts	Insider	Sell	1,457	$109.99	$160,255.43	26,171
1/31/2023	Kevin Charles Gorman	CEO	Sell	2,707	$110.08	$297,986.56	465,278
1/31/2023	Matt Abernethy	CFO	Sell	1,283	$109.98	$141,104.34	21,357
1/6/2023	Eric Benevich	Insider	Sell	400	$125.00	$50,000.00	15,643
1/3/2023	Stephen A. Sherwin	Director	Sell	30,000	$118.86	$3,565,800.00	25,055
11/30/2022	Eric Benevich	Insider	Sell	50,000	$125.90	$6,295,000.00	15,643
11/10/2022	Eric Benevich	Insider	Sell	100	$125.36	$12,536.00	15,643
11/8/2022	Eric Benevich	Insider	Sell	24,593	$125.33	$3,082,240.69	15,643
11/3/2022	Darin Lippoldt	Insider	Sell	4,518	$125.02	$564,840.36	29,234
11/1/2022	Darin Lippoldt	Insider	Sell	10,000	$120.09	$1,200,900.00	29,234
10/31/2022	Gary A. Lyons	Director	Sell	15,000	$114.76	$1,721,400.00	203,697
10/27/2022	Darin Lippoldt	Insider	Sell	4,923	$115.04	$566,341.92	29,234
10/17/2022	Eric Benevich	Insider	Sell	4,960	$110.82	$549,667.20	15,643
10/4/2022	Gary A. Lyons	Director	Sell	5,000	$110.54	$552,700.00	203,697
10/3/2022	David W. Boyer	Insider	Sell	1,437	$106.59	$153,169.83	4,214
8/12/2022	Malcolm Lloyd-Smith	Insider	Sell	21,533	$105.95	$2,281,421.35	18,888
6/27/2022	Julie Cooke	Insider	Sell	754	$100.00	$75,400.00	16,918
5/9/2022	Richard F. Pops	Director	Sell	15,000	$76.30	$1,144,500.00	29,512
4/25/2022	Gary A. Lyons	Director	Sell	15,000	$92.76	$1,391,400.00	208,697
4/1/2022	William H. Rastetter	Director	Sell	10,728	$94.93	$1,018,409.04	34,022
3/22/2022	Darin Lippoldt	Insider	Sell	8,455	$95.05	$803,647.75
3/18/2022	Darin Lippoldt	Insider	Sell	300	$95.00	$28,500.00
2/7/2022	David W. Boyer	Insider	Sell	240	$81.07	$19,456.80
2/7/2022	Kevin Charles Gorman	CEO	Sell	8,710	$80.82	$703,942.20
2/7/2022	Matt Abernethy	CFO	Sell	3,310	$80.79	$267,414.90
1/24/2022	Stephen A. Sherwin	Director	Sell	15,000	$74.43	$1,116,450.00
1/10/2022	Eiry Roberts	Insider	Sell	2,632	$74.50	$196,084.00
1/5/2022	Kyle Gano	Insider	Sell	28,266	$85.50	$2,416,743.00
12/1/2021	Matt Abernethy	CFO	Sell	1,645	$82.59	$135,860.55
10/7/2021	Dimitri E. Grigoriadis	Insider	Sell	8,000	$104.81	$838,480.00
10/7/2021	Gary A. Lyons	Director	Sell	5,000	$105.06	$525,300.00
10/4/2021	Julie Cooke	Insider	Sell	987	$101.73	$100,407.51
8/16/2021	Eric Benevich	Insider	Sell	5,628	$89.62	$504,381.36
7/27/2021	Malcolm Lloyd-Smith	Insider	Sell	16,709	$93.80	$1,567,304.20	15,801
6/10/2021	Gary A. Lyons	Director	Sell	10,000	$100.27	$1,002,700.00

Bitcoin Rockets To Record High But Buy THIS Instead

From Paradigm Press | Ad

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

SEC Filings (Institutional Ownership Changes) for Neurocrine Biosciences (NASDAQ:NBIX)

92.59% of Neurocrine Biosciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Neurocrine Biosciences Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
4/29/2024	Summit Global Investments	49,477	$6.82M	0.5%	+21.5%	0.050%
4/29/2024	China Universal Asset Management Co. Ltd.	19,148	$2.64M	0.3%	+68.5%	0.019%
4/26/2024	Securian Asset Management Inc.	8,149	$1.12M	0.0%	-1.5%	0.008%
4/26/2024	Yousif Capital Management LLC	46,462	$6.41M	0.1%	-0.7%	0.047%
4/26/2024	Peregrine Capital Management LLC	66,776	$9.21M	0.3%	-1.0%	0.067%
4/25/2024	New York State Teachers Retirement System	103,310	$14.25M	0.0%	+1.5%	0.104%
4/25/2024	Mendota Financial Group LLC	750	$0.10M	0.1%	-33.5%	0.001%
4/25/2024	Bank of New York Mellon Corp	921,335	$127.07M	0.0%	-5.9%	0.926%
4/25/2024	Zurcher Kantonalbank Zurich Cantonalbank	63,823	$8.80M	0.0%	+42.0%	0.064%
4/25/2024	Fjarde AP Fonden Fourth Swedish National Pension Fund	42,023	$5.80M	0.1%	+9.1%	0.042%
4/24/2024	Assenagon Asset Management S.A.	337,737	$46.58M	0.1%	+7.0%	0.339%
4/23/2024	Rice Hall James & Associates LLC	126,421	$17.44M	1.0%	-4.0%	0.127%
4/23/2024	Covenant Asset Management LLC	28,306	$3.90M	0.6%	+1.9%	0.028%
4/23/2024	Louisiana State Employees Retirement System	28,600	$3.95M	0.1%	+3.6%	0.029%
4/23/2024	Moody Lynn & Lieberson LLC	22,428	$3.09M	0.2%	N/A	0.023%
4/23/2024	Amalgamated Bank	55,169	$7.61M	0.1%	-18.8%	0.055%
4/22/2024	Raymond James & Associates	60,348	$8.32M	0.0%	+3.9%	0.061%
4/22/2024	EFG Asset Management Americas Corp.	1,774	$0.25M	0.1%	-36.8%	0.002%
4/22/2024	IFM Investors Pty Ltd	18,677	$2.58M	0.0%	+2.4%	0.019%
4/19/2024	First Trust Direct Indexing L.P.	4,130	$0.57M	0.0%	+29.2%	0.004%
4/19/2024	Norden Group LLC	2,848	$0.39M	0.0%	N/A	0.003%
4/19/2024	State of Alaska Department of Revenue	10,795	$1.49M	0.0%	+1.7%	0.011%
4/19/2024	Sumitomo Mitsui Trust Holdings Inc.	252,565	$34.83M	0.0%	+3.5%	0.254%
4/19/2024	Handelsinvest Investeringsforvaltning	2,241	$0.31M	0.1%	-34.2%	0.002%
4/18/2024	State of Michigan Retirement System	24,481	$3.38M	0.0%	+3.8%	0.025%
4/18/2024	Allspring Global Investments Holdings LLC	506,666	$69.88M	0.1%	+23.5%	0.509%
4/17/2024	Hennion & Walsh Asset Management Inc.	6,805	$0.94M	0.1%	+14.3%	0.007%
4/16/2024	Toth Financial Advisory Corp	5,500	$0.76M	0.1%	+34.6%	0.006%
4/16/2024	Sendero Wealth Management LLC	19,563	$2.70M	0.5%	-1.3%	0.020%
4/16/2024	Chesley Taft & Associates LLC	7,500	$1.03M	0.1%	N/A	0.008%
4/16/2024	Wealth Enhancement Advisory Services LLC	4,744	$0.65M	0.0%	+48.5%	0.005%
4/15/2024	Thompson Investment Management Inc.	7,625	$1.05M	0.2%	-1.0%	0.008%
4/12/2024	Washington Capital Management Inc.	4,000	$0.55M	0.4%	-15.8%	0.004%
4/11/2024	Clarus Wealth Advisors	1,490	$0.21M	0.1%	-19.1%	0.001%
4/11/2024	Tealwood Asset Management Inc.	12,008	$1.66M	0.7%	-2.0%	0.012%
4/10/2024	Park Avenue Securities LLC	9,570	$1.32M	0.0%	+1.1%	0.010%
4/10/2024	Banque Cantonale Vaudoise	1,186	$0.16M	0.0%	+197.2%	0.001%
4/9/2024	Woodstock Corp	7,509	$1.04M	0.1%	-26.2%	0.008%
4/9/2024	Rise Advisors LLC	352	$49K	0.0%	+576.9%	0.000%
4/9/2024	Mather Group LLC.	198	$26K	0.0%	N/A	0.000%
4/5/2024	First Hawaiian Bank	5,163	$0.71M	0.0%	-2.0%	0.005%
4/5/2024	Juncture Wealth Strategies LLC	8,425	$1.16M	0.5%	+4.2%	0.008%
4/5/2024	GAMMA Investing LLC	1,158	$0.16M	0.0%	+36.6%	0.001%
4/5/2024	Los Angeles Capital Management LLC	245,381	$33.84M	0.1%	-73.3%	0.247%
4/5/2024	CWM LLC	4,664	$0.64M	0.0%	+60.7%	0.005%
3/29/2024	Kapitalo Investimentos Ltda	503	$66K	0.0%	N/A	0.001%
3/26/2024	HighPoint Advisor Group LLC	2,510	$0.35M	0.0%	N/A	0.003%
3/22/2024	PNC Financial Services Group Inc.	3,247	$0.43M	0.0%	-11.0%	0.003%
3/21/2024	Healthcare of Ontario Pension Plan Trust Fund	71,000	$9.36M	0.0%	N/A	0.071%
3/11/2024	Vanguard Group Inc.	9,710,328	$1.28B	0.0%	+1.6%	9.758%
3/5/2024	Fisher Asset Management LLC	60,227	$7.94M	0.0%	-2.6%	0.061%
3/5/2024	Wellington Management Group LLP	1,199,542	$158.05M	0.0%	-9.7%	1.205%
3/1/2024	Goldman Sachs Group Inc.	691,632	$91.13M	0.0%	-12.1%	0.695%
2/28/2024	American International Group Inc.	133,543	$17.60M	0.1%	-3.5%	0.134%
2/26/2024	Teachers Retirement System of The State of Kentucky	31,280	$4.12M	0.0%	-4.9%	0.031%
2/26/2024	Perceptive Advisors LLC	270,794	$35.68M	0.8%	+70.1%	0.272%
2/21/2024	American Trust	2,680	$0.35M	0.0%	-12.1%	0.003%
2/20/2024	Quarry LP	300	$40K	0.0%	-84.2%	0.000%
2/20/2024	Aurora Investment Counsel	13,726	$1.81M	1.1%	+2.6%	0.014%
2/15/2024	Parkman Healthcare Partners LLC	140,116	$18.46M	2.6%	+67.1%	0.141%
2/14/2024	Braidwell LP	715,209	$94.24M	3.5%	-26.1%	0.719%
2/14/2024	Point72 Asset Management L.P.	1,391,970	$183.41M	0.4%	-46.0%	1.399%
2/14/2024	Avidity Partners Management LP	658,000	$86.70M	3.2%	+0.9%	0.661%
2/14/2024	First Financial Bankshares Inc	15,802	$2.08M	0.1%	N/A	0.016%
2/14/2024	Superstring Capital Management LP	29,346	$3.87M	2.8%	N/A	0.029%
2/14/2024	Bellevue Group AG	2,430,500	$320.24M	4.9%	-5.9%	2.442%
2/14/2024	Scout Investments Inc.	261,618	$34.47M	0.9%	-28.5%	0.263%
2/14/2024	Seven Eight Capital LP	7,215	$0.95M	0.1%	N/A	0.007%
2/14/2024	Vestal Point Capital LP	800,000	$105.41M	11.2%	N/A	0.804%
2/14/2024	Sectoral Asset Management Inc.	4,445	$0.59M	0.3%	+10.2%	0.004%
2/14/2024	Prudential PLC	19,931	$2.63M	0.0%	-3.0%	0.020%
2/13/2024	Vinva Investment Management Ltd	4,801	$0.63M	0.0%	+15.7%	0.005%
2/13/2024	Stephens Inc. AR	6,888	$0.91M	0.0%	+16.1%	0.007%
2/13/2024	American International Group Inc.	133,543	$17.60M	0.1%	-3.5%	0.136%
2/13/2024	Public Employees Retirement Association of Colorado	11,684	$1.54M	0.0%	+67.3%	0.012%
2/13/2024	1832 Asset Management L.P.	41,000	$5.40M	0.0%	N/A	0.042%
2/13/2024	Oppenheimer & Co. Inc.	17,169	$2.26M	0.0%	+1.5%	0.017%
2/13/2024	Crossmark Global Holdings Inc.	8,056	$1.06M	0.0%	-5.7%	0.008%
2/13/2024	Tower Research Capital LLC TRC	14,153	$1.87M	0.0%	+36.8%	0.014%
2/13/2024	Armistice Capital LLC	1,048,000	$138.08M	1.9%	-13.8%	1.067%
2/13/2024	Eisler Capital UK Ltd.	6,843	$0.90M	0.0%	N/A	0.007%
2/13/2024	Affinity Asset Advisors LLC	10,000	$1.32M	0.2%	N/A	0.010%
2/13/2024	First Trust Advisors LP	590,725	$77.83M	0.1%	+27.4%	0.601%
2/13/2024	Goldman Sachs Group Inc.	691,632	$91.13M	0.0%	-12.1%	0.704%
2/13/2024	Rafferty Asset Management LLC	76,549	$10.09M	0.0%	-6.1%	0.078%
2/13/2024	Rhenman & Partners Asset Management AB	62,000	$8.17M	0.8%	+13.6%	0.063%
2/13/2024	CIBC Asset Management Inc	3,240	$0.43M	0.0%	-6.6%	0.003%
2/13/2024	The Manufacturers Life Insurance Company	116,955	$15.41M	0.0%	+18.3%	0.119%
2/13/2024	KBC Group NV	10,582	$1.39M	0.0%	-64.5%	0.011%
2/13/2024	APG Asset Management US Inc.	18,534	$2.44M	0.0%	N/A	0.019%
2/13/2024	California State Teachers Retirement System	144,731	$19.07M	0.0%	-0.6%	0.147%
2/12/2024	Eagle Asset Management Inc.	728,353	$95.97M	0.5%	+0.1%	0.741%
2/12/2024	Bank of Nova Scotia	8,216	$1.08M	0.0%	+27.8%	0.008%
2/12/2024	Claret Asset Management Corp	1,565	$0.21M	0.0%	N/A	0.002%
2/12/2024	Capstone Investment Advisors LLC	2,394	$0.32M	0.0%	-28.5%	0.002%
2/12/2024	TFO Wealth Partners LLC	3,180	$0.40M	0.0%	+105,900.0%	0.003%
2/12/2024	Treasurer of the State of North Carolina	68,819	$9.07M	0.0%	+0.8%	0.070%
2/12/2024	Weiss Asset Management LP	14,496	$1.91M	0.1%	N/A	0.015%
2/12/2024	Allianz Asset Management GmbH	29,608	$3.90M	0.0%	-63.9%	0.030%
2/12/2024	TD Asset Management Inc	104,219	$13.73M	0.0%	+87.1%	0.106%

Data available starting January 2016

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Today's Range

Now: $138.89

$136.05

$139.37

50 Day Range

MA: $136.63

$130.40

$143.74

52 Week Range

Now: $138.89

$89.04

$148.37

Volume

681,739 shs

Average Volume

845,887 shs

Market Capitalization

$13.82 billion

P/E Ratio

57.39

Dividend Yield

N/A

Beta

0.25

Who are the company insiders with the largest holdings of Neurocrine Biosciences?: Neurocrine Biosciences' top insider shareholders include:
Neurocrine Biosciences Inc (Major Shareholder)
Kevin Charles Gorman (CEO)
Gary A Lyons (Director)
Kyle Gano (Insider)
William H Rastetter (Director)
Eric Benevich (Insider)
Darin Lippoldt (Insider)
Matt Abernethy (CFO)
Eiry Roberts (Insider)
Richard F Pops (Director)
Stephen A Sherwin (Director)
Malcolm Lloyd-Smith (Insider)
Julie Cooke (Insider)
Jude Onyia (Insider)
Ingrid Delaet (Insider)
David W Boyer (Insider)
George J Morrow (Director)
Leslie V Norwalk (Director)
Learn More about top insider investors at Neurocrine Biosciences.
Who are the major institutional investors of Neurocrine Biosciences?: Neurocrine Biosciences' top institutional investors include:
Bank of New York Mellon Corp — 0.93%
Allspring Global Investments Holdings LLC — 0.51%
Assenagon Asset Management S.A. — 0.34%
Sumitomo Mitsui Trust Holdings Inc. — 0.25%
Los Angeles Capital Management LLC — 0.25%
Rice Hall James & Associates LLC — 0.13%
Learn More about top institutional investors of Neurocrine Biosciences stock.
Which institutional investors are selling Neurocrine Biosciences stock?: During the previous quarter, NBIX stock was sold by these institutional investors:
Los Angeles Capital Management LLC
Bank of New York Mellon Corp
Amalgamated Bank
Rice Hall James & Associates LLC
Woodstock Corp
Handelsinvest Investeringsforvaltning
EFG Asset Management Americas Corp.
Washington Capital Management Inc.
During the previous year, company insiders that have sold Neurocrine Biosciences company stock include:
Neurocrine Biosciences Inc (Major Shareholder)
Kevin Charles Gorman (CEO)
Gary A Lyons (Director)
Kyle Gano (Insider)
William H Rastetter (Director)
Eric Benevich (Insider)
Darin Lippoldt (Insider)
Matt Abernethy (CFO)
Eiry Roberts (Insider)
Richard F Pops (Director)
Stephen A Sherwin (Director)
Malcolm Lloyd-Smith (Insider)
Julie Cooke (Insider)
Jude Onyia (Insider)
Ingrid Delaet (Insider)
Learn More investors selling Neurocrine Biosciences stock.
Which institutional investors are buying Neurocrine Biosciences stock?: Within the previous quarter, NBIX stock was bought by institutional investors including:
Allspring Global Investments Holdings LLC
Moody Lynn & Lieberson LLC
Assenagon Asset Management S.A.
Zurcher Kantonalbank Zurich Cantonalbank
Simplex Trading LLC
Summit Global Investments
Sumitomo Mitsui Trust Holdings Inc.
China Universal Asset Management Co. Ltd.